Vivos Therapeutics, a medical technology company specializing in developing and commercializing innovative diagnostic and treatment methods for breathing-related sleep issues, has announced its fiscal 2022 financial results and provided an operational update. The company’s accomplishments in 2022 and early 2023 set the stage for potential revenue growth in 2023.
The medical device and technology company reported revenue of $16 million for the full year ended December 31, 2022. The revenue growth is expected to continue in the future with the company’s focus on leveraging its core strengths and proprietary technology to create new and diverse revenue streams.
Vivos Therapeutics aims to address breathing-related sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults. The company’s innovative diagnostic and treatment methods have been designed to target the root causes of these issues, rather than just treating the symptoms.
One of the key strengths of Vivos Therapeutics is its patented Vivos System, which is a non-surgical, non-invasive medical device designed to correct craniofacial abnormalities. The device works by gently stimulating bone growth in the maxilla and mandible, resulting in a more open airway for breathing during sleep. The Vivos System has been clinically proven to be an effective treatment for mild-to-moderate OSA and snoring in adults, without the need for surgery or medications.
In addition to the Vivos System, the company is also developing other innovative diagnostic and treatment methods for breathing-related sleep issues. One such method is the VivosScore, a proprietary diagnostic tool designed to assess a patient’s risk of developing OSA and other sleep-related breathing disorders. The VivosScore is based on a comprehensive evaluation of a patient’s facial anatomy, airway function, and other clinical factors.
The company is also working on developing new products and services that leverage its core strengths and proprietary technology to create new revenue streams. These products and services include the VivosHub, a cloud-based platform for managing patient data and treatment plans, and the VivosPilot, a comprehensive training program for healthcare professionals on the Vivos System and other breathing-related sleep issues.
Vivos Therapeutics’ fiscal 2022 financial results and operational update demonstrate the company’s commitment to providing innovative solutions for breathing-related sleep issues. With its focus on leveraging its core strengths and proprietary technology to create new revenue streams, the company is well-positioned for potential revenue growth in 2023 and beyond.
Vivos Therapeutics’ commitment to innovation and its patient-centered approach has earned it a strong reputation in the medical technology industry. The company’s success is driven by its dedicated team of professionals who are committed to delivering high-quality products and services to patients worldwide.
Moreover, Vivos Therapeutics’ success is not limited to financial performance alone. The company has also made significant contributions to the medical community by raising awareness about the link between certain dentofacial abnormalities and breathing-related sleep issues. Its research and development efforts have yielded a wealth of knowledge that is helping to shape the future of sleep medicine.
As the company continues to expand its reach and develop new technologies, it remains committed to its mission of improving the quality of life for patients suffering from breathing-related sleep issues. Vivos Therapeutics’ innovative products and services are changing the way these conditions are diagnosed and treated, and its impact on the medical community is sure to be felt for years to come.
In conclusion, Vivos Therapeutics’ fiscal 2022 financial results and operational update underscore the company’s commitment to innovation and its patient-centered approach. With a strong pipeline of new products and technologies in development, the company is poised to continue its growth trajectory and remain a leader in developing innovative diagnostic and treatment methods for patients suffering from breathing-related sleep issues.
